• Executive Summary
o Market overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 - 2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Application
o Market segments
o Comparison by Application
o Therapeutics - Market size and forecast 2020-2025
o Diagnostics - Market size and forecast 2020-2025
o Market opportunity by Application
• Customer landscape
o Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America - Market size and forecast 2020-2025
o Europe - Market size and forecast 2020-2025
o Asia - Market size and forecast 2020-2025
o ROW - Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o 4D pharma Plc
o ENTEROME SA
o Evelo Biosciences Inc.
o Ferring Pharmaceuticals AS
o Osel Inc.
o Second Genome Therapeutics
o Seres Therapeutics Inc.
o Synlogic Inc.
o Synthetic Biologics Inc.
o Vedanta Biosciences Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global - Market size and forecast 2020 - 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 - 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition - Five forces 2020
• 21: Application - Market share 2020-2025 (%)
• 22: Comparison by Application
• 23: Therapeutics - Market size and forecast 2020-2025 ($ million)
• 24: Therapeutics - Year-over-year growth 2020-2025 (%)
• 25: Diagnostics - Market size and forecast 2020-2025 ($ million)
• 26: Diagnostics - Year-over-year growth 2020-2025 (%)
• 27: Market opportunity by Application
• 28: Customer landscape
• 29: Market share by geography 2020-2025 (%)
• 30: Geographic comparison
• 31: North America - Market size and forecast 2020-2025 ($ million)
• 32: North America - Year-over-year growth 2020-2025 (%)
• 33: Europe - Market size and forecast 2020-2025 ($ million)
• 34: Europe - Year-over-year growth 2020-2025 (%)
• 35: Asia - Market size and forecast 2020-2025 ($ million)
• 36: Asia - Year-over-year growth 2020-2025 (%)
• 37: ROW - Market size and forecast 2020-2025 ($ million)
• 38: ROW - Year-over-year growth 2020-2025 (%)
• 39: Key leading countries
• 40: Market opportunity by geography ($ million)
• 41: Impact of drivers and challenges
• 42: Vendor landscape
• 43: Landscape disruption
• 44: Industry risks
• 45: Vendors covered
• 46: Market positioning of vendors
• 47: 4D pharma Plc - Overview
• 48: 4D pharma Plc - Product and service
• 49: 4D pharma Plc - Key offerings
• 50: 4D pharma Plc - Key customers
• 51: 4D pharma Plc - Segment focus
• 52: ENTEROME SA - Overview
• 53: ENTEROME SA - Product and service
• 54: ENTEROME SA - Key offerings
• 55: ENTEROME SA - Key customers
• 56: ENTEROME SA - Segment focus
• 57: Evelo Biosciences Inc. - Overview
• 58: Evelo Biosciences Inc. - Product and service
• 59: Evelo Biosciences Inc. - Key offerings
• 60: Evelo Biosciences Inc. - Key customers
• 61: Evelo Biosciences Inc. - Segment focus
• 62: Ferring Pharmaceuticals AS - Overview
• 63: Ferring Pharmaceuticals AS - Product and service
• 64: Ferring Pharmaceuticals AS - Key offerings
• 65: Ferring Pharmaceuticals AS - Key customers
• 66: Ferring Pharmaceuticals AS - Segment focus
• 67: Osel Inc. - Overview
• 68: Osel Inc. - Product and service
• 69: Osel Inc. - Key offerings
• 70: Osel Inc. - Key customers
• 71: Osel Inc. - Segment focus
• 72: Second Genome Therapeutics - Overview
• 73: Second Genome Therapeutics - Product and service
• 74: Second Genome Therapeutics - Key offerings
• 75: Second Genome Therapeutics - Key customers
• 76: Second Genome Therapeutics - Segment focus
• 77: Seres Therapeutics Inc. - Overview
• 78: Seres Therapeutics Inc. - Product and service
• 79: Seres Therapeutics Inc. - Key offerings
• 80: Seres Therapeutics Inc. - Key customers
• 81: Seres Therapeutics Inc. - Segment focus
• 82: Synlogic Inc. - Overview
• 83: Synlogic Inc. - Product and service
• 84: Synlogic Inc. - Key offerings
• 85: Synlogic Inc. - Key customers
• 86: Synlogic Inc. - Segment focus
• 87: Synthetic Biologics Inc. - Overview
• 88: Synthetic Biologics Inc. - Product and service
• 89: Synthetic Biologics Inc. - Key offerings
• 90: Synthetic Biologics Inc. - Key customers
• 91: Synthetic Biologics Inc. - Segment focus
• 92: Vedanta Biosciences Inc. - Overview
• 93: Vedanta Biosciences Inc. - Product and service
• 94: Vedanta Biosciences Inc. - Key offerings
• 95: Vedanta Biosciences Inc. - Key customers
• 96: Vedanta Biosciences Inc. - Segment focus
• 97: Currency conversion rates for US$
• 98: Research Methodology
• 99: Validation techniques employed for market sizing
• 100: Information sources
• 101: List of abbreviations

Companies Mentioned
4D pharma Plc
. ENTEROME SA
. Evelo Biosciences Inc.
. Ferring Pharmaceuticals AS
. Osel Inc.
. Second Genome Therapeutics
. Seres Therapeutics Inc.
. Synlogic Inc.
. Synthetic Biologics Inc.
. Vedanta Biosciences Inc.